The state of peptide search in 2026
Aggregate search volume, year-on-year growth, and the narrative drivers behind them. Peptides overtook Ozempic in US searches; GHK-Cu (+1,016%) is the single fastest-rising molecule we track.
US monthly searches10.1MPeptides (all variants)
Peptide therapy YoY+281%Google
Peptide therapy TikTok+459%TikTok YoY
Weight-loss share60%of all peptide queries
Fastest-rising YoY
% change vs last year
- 1GHK-Cu (topical)+1016%+1,016% YoY — fastest riser across all peptides.
- 2GHK-Cu (injectable)+1016%
- 3NAD++601%Co-searched with 'peptide therapy'.
- 4Orforglipron+520%First viable oral GLP-1 — searches exploding.
- 5Retatrutide+512%Fastest-rising GLP-class search.
- 6Cagrilintide+310%
- 7LL-37+250%
- 8Tirzepatide+240%Dominant GLP-1; nearly 2x #2 peptide.
- 9MOTS-c+240%Mitochondrial peptide — sleeper longevity category.
- 10DIHEXA+220%
- 11PT-141+180%
- 12KPV+180%
Highest search volume
US monthly searches (Jan 2026)
- 1Tirzepatide1.0MDominant GLP-1; nearly 2x #2 peptide.
- 2Semaglutide600K
- 3Retatrutide280KFastest-rising GLP-class search.
- 4GHK-Cu (topical)220K+1,016% YoY — fastest riser across all peptides.
- 5NAD+180KCo-searched with 'peptide therapy'.
- 6BPC-157165KTop non-weight-loss peptide.
- 7Orforglipron140KFirst viable oral GLP-1 — searches exploding.
- 8GHK-Cu (injectable)110K
- 9TB-50095KAlmost always paired with BPC-157 in searches.
- 10MK-677 (Ibutamoren)95K
- 11CJC-129585K
- 12Melanotan II85K
The big narrative drivers
- ●Joe Rogan credited peptides for injury recovery on-air; influencer coverage followed.
- ●RFK Jr / HHS Feb 2026 reclassification — roughly 14 previously restricted peptides returned to legal compounding in the US.
- ●$328M gray-market imports from China in 2025 pushed demand underground before policy caught up.
- ●Beauty industry halo — K-18, Ouai, Glow Recipe, The Ordinary pushed peptide terminology into mainstream cosmetics.